Toggle Main Menu Toggle Search

Open Access padlockePrints

Frequency and outcomes of gastrostomy insertion in a longitudinal cohort study of atypical parkinsonism

Lookup NU author(s): Professor Nicola PaveseORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.Background: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) show a high prevalence and rapid progression of dysphagia, which is associated with reduced survival. Despite this, the evidence base for gastrostomy is poor, and the optimal frequency and outcomes of this intervention are not known. We aimed to characterise the prevalence and outcomes of gastrostomy in patients with these three atypical parkinsonian disorders. Method: We analysed data from the natural history and longitudinal cohorts of the PROSPECT-M-UK study with up to 60 months of follow-up from baseline. Survival post-gastrostomy was analysed using Kaplan–Meier survival curves. Results: In a total of 339 patients (mean age at symptom onset 63.3 years, mean symptom duration at baseline 4.6 years), dysphagia was present in >50% across all disease groups at baseline and showed rapid progression during follow-up. Gastrostomy was recorded as recommended in 44 (13%) and performed in 21 (6.2%; MSA 7, PSP 11, CBS 3) of the total study population. Median survival post-gastrostomy was 24 months compared with 12 months where gastrostomy was recommended but not done (p = 0.008). However, this was not significant when correcting for age and duration of symptoms at the time of procedure or recommendation. Conclusions: Gastrostomy was performed relatively infrequently in this cohort despite the high prevalence of dysphagia. Survival post-gastrostomy was longer than previously reported, but further data on other outcomes and clinician and patient perspectives would help to guide use of this intervention in MSA, PSP and CBS.


Publication metadata

Author(s): Kobylecki C, Chelban V, Goh YY, Michou E, Fumi R, TheilmannJensen M, Mohammad R, Costantini A, Vijiaratnam N, Pavey S, Pavese N, Leigh PN, Rowe JB, Hu MT, Church A, Morris HR, Houlden H

Publication type: Article

Publication status: Published

Journal: European Journal of Neurology

Year: 2024

Pages: epub ahead of print

Online publication date: 26/04/2024

Acceptance date: 08/02/2024

Date deposited: 11/04/2024

ISSN (print): 1351-5101

ISSN (electronic): 1468-1331

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/ene.16258

DOI: 10.1111/ene.16258

PubMed id: 38407533


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
MSA Coalition, Medical Research Council (MRC UK MR/J004758/1, G0802760, G1001253; MC_UU_00030/14; MR/T033371/1)
Multiple System Atrophy Trust (PROSPECT-M- UK Project)
Multiple System Atrophy Coalition (Grant 567540)
the Cambridge Centre for Parkinson-Plus
the King Baudouin Foundation/Sophia Fund
the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312)
the Guarantors of Brain (Grant 565908)
the MSA Trust and the PSP Association (PROSPECT-M- UK)
the Multiple System Atrophy Trust/ABN Clinical Research Training Fellowship (Grant F84 ABN 540868)
Wellcome Trust (equipment and strategic awards WT093205MA and WT104033/Z/14/Z; and 220258)

Share